EN | TR
E-ISSN: 3061-9947
Evaluation of General Clinicopathological Features in Patients with Esophageal Cancer and Determination of Factors Affecting Prognosis
PDF
Cite
Share
Request
Original Article
VOLUME: 53 ISSUE: 2
P: 294-308
2020

Evaluation of General Clinicopathological Features in Patients with Esophageal Cancer and Determination of Factors Affecting Prognosis

Acta Haematol Oncol Turc 2020;53(2):294-308
DOI: 10.5505/aot.2020.68335
Fatma Buğdaycı Başal 1
Ferit Aslan 2
Erkan Erdur 3
İrem Bilgetekin 1
Berna Öksüzoğlu 1
Umut Demirci 4
1. HSU, Dr. A.Y. Ankara Oncology Training And Research Hospital, Department of Medical Oncology, Ankara
2. Yüksek İhtisas University, Ankara-Batıkent Medical Park Hospital, Department of Medical Oncology, Ankara
3. HSU, Gazi Yaşargil Training And Research Hospital, Department of Medical Oncology, Diyarbakır
4. Üsküdar University, Ankara Memorial Hospital, Department of Medical Oncology, Ankara
5.
No information available.
No information available
Received Date: 2020-06-30T01:55:04
Accepted Date: 2020-09-04T11:08:56
PDF
Cite
Share
Request

Abstract

INTRODUCTION

In this study, it was aimed to evaluate the single-center observational data of 182 patients with esophageal cancers, to examine their clinical and demographic features and to analyze other prognostic factors including multimodal treatment

METHODS

Within the scope of the study, medical records of 182 patients diagnosed with esophageal cancer between January 2010 and December 2019 were included. The demographic, clinical, pathological features, treatment and side effects of the patients were obtained from the file records. Survival analyzes were evaluated by the Kaplan-Meier test, univariate analyzes by the Log-Rank test, and multivariate analyzes by the Cox-Regression test

RESULTS

The most common histopathological type is squamous cell cancer (n: 153, 84.1%) and the most common tumor localization in the patients is located at the lower part. Systemic treatments applied were adjuvant chemo (radiotherapy) 6%, neoadjuvant chemotherapy 2.7%, neoadjuvant chemoradiotherapy 30.8% and definitive chemoradiotherapy 37.9%. Distant metastatic patients were also included in the study group. In univariate analysis, the difference in overall survival (OS) and progression-free survival (PFS) was determined in terms of differentiation, presence of multimodal therapy, resection type, neoadjuvant treatment response, and presence of metastases (p <0.05). In multivariate analysis, it was observed that surgical margin negativity decreased the progression risk by 3.4 times (p <0.001), and the presence of lymphovascular invasion (LVI) increased the risk of progression by 1.9 times (p = 0.004). In terms of overall survival, it was observed that the only prognostic factor was surgical margin negativity and decreased the risk of death by 2.4 times (p <0.001).

DISCUSSION AND CONCLUSION

As a result, observational data belonging to a single center were presented and findings compatible with the literature regarding the treatment response, resection type, histological subtype and tumor localization were obtained. In terms of prognostic factors, LVI and surgical margin negativity have been shown to be strong prognostic factors.